Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)’s Financial Overview

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) declined -5.97% yesterday to close its trading session at $5.51. The company has 1 year Price Target of $9.67. Merrimack Pharmaceuticals, Inc. has 52-Week high of $9.22 and 52-Week Low of $4.39. The stock touched its 52-Week High on Dec 3, 2015 and 52-Week Low on Sep 12, 2016. The stock traded with the volume of 2.75 Million shares yesterday. The firm shows the market capitalization of $714.21 Million.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.23/share against the analyst consensus estimate of $-0.27/share. The difference between the actual and expected EPS is $0.04 a share with a surprise factor of 14.8%.

The firm is trading with SMA20 of -7.81 Percent, SMA50 of -3.23 Percent and SMA200 of -10.39 percent. Merrimack Pharmaceuticals, Inc. has P/S value of 6.83 while its P/B value stands at 0. Similarly, the company has Return on Assets of -96 percent, Return on Equity of 80.6 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 96.5 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK). On 7-Oct-16 JP Morgan Downgrade Merrimack Pharmaceuticals, Inc. Stock  to Neutral. Another firm also rated the stock on 27-May-16 where Robert W. Baird Initiated the stock to Neutral.

The Stock currently has Analyst’ mean Recommendation of 2.6 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 3 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +27.04% increase from the last price of 5.51.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

CSX Corp. (NASDAQ:CSX)

CSX Corporation’s unique combination of rail, container-shipping, intermodal and logistics services provides global reach that’s second to none. The company’s goal, advanced at each of its business units, is to provide efficient, competitive transportation and related services for customers.

CSX Corp. (NASDAQ:CSX)’s Financial Outlook

The 27 analysts offering 12-month price forecasts for CSX Corp have a median target of 33.00, with a high estimate of 37.00 and a low estimate of 18.00. The median estimate represents a -7.85% decrease from the last price of 35.81.

CSX Corporation is estimated to report earnings on  01/10/2017. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 13 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.47.  The reported EPS for the same quarter last year was $0.48.

According to Zacks Investment Research, CSX Corp. has a Consensus Recommendation of 2.47. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 2.9% and closed its last trading session at $35.81. The company has the market capitalization of $33.54 Billion. The stock has 52-week high of $36.09 and 52-Week low of $21.33. The firm touched its 52-Week high on Nov 30, 2016 and 52-Week low on Jan 20, 2016. The company has volume of 11.32 Million shares. The company has a total of 936.66 Million shares outstanding.

CSX Corp. (NASDAQ:CSX) in the last quarter reported its actual EPS of $0.48/share where the analyst estimated EPS was $0.45/share. The difference between the actual and Estimated EPS is $0.03. This shows a surprise factor of 6.7 percent.

The company has YTD performance of 41.62 percent. Beta for CSX Corp. stands at 1.17 while its ATR (average true range) is 0.66. The company has Weekly Volatility of 1.58%% and Monthly Volatility of 1.91%%.

CSX Corp. has distance from 20-day Simple Moving Average (SMA20) of 7.28%, Distance from 50-Day Simple Moving Average of 13.73 percent and Distance from 200-Day Simple Moving Average of 29.62%.

The Company currently has ROA (Return on Assets) of 5 percent, Return on Equity (ROE) of 14.8 Percent and Return on Investment (ROI) of 10.9% with Gross margin of 73.7 percent and Operating & Profit margin of 29.4% and 15.9% respectively.